Showing results (1-10 of 14) with videos related to
Sort By:
Pageof 2
Current Diabetes Reports|July 24, 2019
Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk RecognitionPaul D RosenblitCurrent Cardiology Reports|January 4, 2012
Do persons with diabetes benefit from combination statin and fibrate therapy?Paul D RosenblitCurrent Diabetes Reports|November 23, 2019
Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD RiskPaul D RosenblitCardiovascular Diabetology|July 16, 2016
Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?Paul D RosenblitCurrent Diabetes Reports|November 8, 2019
Correction to: Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk RecognitionPaul D RosenblitCurrent Cardiology Reports|September 28, 2018
Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?Yixing Li, Paul D RosenblitCardiovascular Diagnosis and Therapy|May 23, 2017
Advances in dyslipidemia management for prevention of atherosclerosis: PCSK9 monoclonal antibody therapy and beyondNathan D Wong, Paul D Rosenblit, Robert S GreenfieldJournal of Clinical Lipidology|August 1, 2015
Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010Nathan D Wong, Joanna Chuang, Yanglu Zhao, et al.BMJ Open Diabetes Research & Care|September 21, 2016
Impact of symptomatic upper respiratory tract infections on insulin absorption and action of Technosphere inhaled insulinPhilip A Levin, Lutz Heinemann, Anders Boss, et al.Diabetes Technology & Therapeutics|August 3, 2012
A comprehensive evaluation of the performance of the test strip technology for OneTouch Verio glucose meter systemsTimothy Bailey, Anna Chang, Paul D Rosenblit, et al.Pageof 2